New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:10 EDTSIRI, ZGNX, BODY, ACHN, EBIX, RVLT, PLUG, ULTA, GIS, ARO, LMCA, FSYSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ulta Salon (ULTA), up 6%... Ebix (EBIX), up 7.5%... Revolution Lighting (RVLT), up 12%. ALSO HIGHER: Liberty Media (LMCA), up 7% after announcing plans for two new tracking stock groups, saying its offer for Sirius XM (SIRI) is no longer applicable... Achillion (ACHN), up 4.4% after announcing clinical results for ACH-3102. DOWN AFTER EARNINGS: Aeropostale (ARO), down 15%... Fuel Systems (FSYS), down 13%. ALSO LOWER: Sirius XM, down 1.5% after Liberty Media said its offer for Sirius was no longer applicable... General Mills (GIS), down 3.2% after warning on Q3 earnings... Plug Power (PLUG), down 3% following downgrades at Cowen and Roth Capital... Body Central (BODY), down 10% after to delay filing 10-K... Zogenix (ZGNX), down 7.4% following report that Senator Manchin introduced a bill to ban Zohydro.
News For SIRI;LMCA;ARO;GIS;ULTA;PLUG;RVLT;EBIX;ACHN;BODY;ZGNX;FSYS From The Last 14 Days
Check below for free stories on SIRI;LMCA;ARO;GIS;ULTA;PLUG;RVLT;EBIX;ACHN;BODY;ZGNX;FSYS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 18, 2014
16:36 EDTAROAeropostale sees Q2 adjusted EPS (45c)-(42c), consensus (58c)
Subscribe for More Information
16:32 EDTAROAeropostale announces Julian Geiger to rejoin company as CEO
Subscribe for More Information
10:01 EDTACHNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
09:03 EDTACHNOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTEBIXEbix partners with ANMF
Ebix announced that the Company's A.D.A.M. Health Content Division has executed a contract with the Australian Nursing and Midwifery Federation, or ANMF, to offer a range of health related continuing professional development, or CPD, courses to its members on an annual subscription basis. As a part of the partnership, the co-branded Ebix-ANMF Body System Training Room, or BSTR, has been launched as an educational web portal, to provide low cost subscription access to a range of continuing professional development, or CPD, courses covering anatomy and physiology, disease and disease management, and medical procedures. The eLearning courses are provided by A.D.A.M. OnDemand and offered to the ANMF's members, non-members and corporate clients who register for an annual subscription of CPD.
07:28 EDTACHNAchillion upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
06:34 EDTFSYSFuel Systems sees FY14 revenue $335M-$355M, consensus $347.13M
Subscribe for More Information
06:33 EDTFSYSFuel Systems 'undergoing transition in end markets'
Subscribe for More Information
06:30 EDTFSYSFuel Systems reports Q2 EPS excl. items (5c), consensus 2c
Subscribe for More Information
06:09 EDTAROAeropostale volatility elevated into Q2 and new leadership outlook
Aeropostale September call option implied volatility is at 93, October is at 75, January is at 85; compared to its 26-week average of 58 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on August 21.
August 15, 2014
17:16 EDTFSYSBecker Drapkin reports 6.4% stake in Fuel Systems
Subscribe for More Information
16:38 EDTACHNOn The Fly: Closing Wrap
Stocks on Wall Street began the session in positive territory despite some soft economic data points, including a weaker than expected report on manufacturing in the New York area and a lower than expected consumer confidence reading. The market short circuited following reports of a skirmish in the Ukraine where a Russian convoy was supposedly fired upon when it crossed the border. The averages quickly dropped and were only able to partially recover, as investors moved to the sidelines to avoid additional geopolitical risk over the weekend. ECONOMIC EVENTS: The NY Fed's Empire manufacturing survey had a reading of 14.69, versus expectations for a 20.0 reading. The Producer Price Index increased 0.1% overall, matching expectations. The core reading was up 0.2%, which was also in-line with the consensus forecast. Industrial production increased 0.4% in July, beating the consensus 0.2% growth forecast. That nudged up capacity utilization to 79.2%, versus 79.1% previously. The first University of Michigan consumer confidence reading for August fell 2.6 points to 79.2, versus expectations for it to have edged up to 82.0. Treasury international capital data showed foreigners dumped $153.5B in total U.S. assets in July after buying a revised $33.1B in June. COMPANY NEWS: Shares of Monster Beverage (MNST) surged $21.84, or 30.48%, to $93.49 after Coca-Cola (KO) bought a stake in the energy drink maker and the companies announced a long-term strategic partnership and asset swap. Coca-Cola will pay $2.15B for a 16.7% stake in Monster, the companies announced last night. Under the terms of their agreement, Coca-Cola will add two directors to Monster's board. Coke will transfer ownership of its worldwide energy business including brands like NOS, Full Throttle, Burn, Mother, Play and Power Play, and Relentless to Monster, in trade for which Monster will transfer its non-energy business to Coke. MAJOR MOVERS: Among the notable gainers was Achillion Pharmaceuticals (ACHN), which rose 81c, or 9.6%, to $9.25 after the company announced interim results from an ongoing Phase 2 proxy study of a potential chronic hepatitis C virus regimen that analysts at Piper Jaffray called "impressive." Also higher was Paylocity (PCTY), which advanced $2.17, or 9.79%, to $24.34 after reporting better than expected fourth quarter revenue and guiding to higher than expected sales in its first quarter. Among the noteworthy losers was retailer J.C. Penney (JCP), which fell 24c, or 2.46%, to $9.50 despite posting a narrower than expected loss for the second quarter. Also lower were shares of another department store owner, Dillard's (DDS), which dropped $9.49, or 8.21%, to $106.11 after reporting quarterly results that missed expectations. INDEXES: The Dow dropped 50.67, or 0.3%, to 16,662.91, the Nasdaq gained 11.92, or 0.27%, to 4,464.93, and the S&P 500 slipped 0.12, or 0.01%, to 1,955.06.
12:39 EDTACHNOn The Fly: Midday Wrap
Subscribe for More Information
10:03 EDTACHNAchillion ACH-3102 data results 'impressive,' says Piper Jaffray
Piper Jaffray calls this morning's data for Achillion's ACH-3102 "impressive," saying the numbers validate the potential for combining ACH-3102 with a nuc. Piper still believes a potential acquirer could show interest in Achillion this fall given the relative near-term data releases. It has an Overweight rating on the stock with a $10 price target.
10:01 EDTACHNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:10 EDTACHNOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTFSYSFuel Systems weekly volatility elevated into Q2 and outlook
Fuel Systems September call option implied volatility is at 56, October is at 47, January is at 46; compared to its 26-week average of 48 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on August 18.
07:11 EDTACHNAchillion achieves 100% SVR4 in Phase 2 trial of ACH-3102 and sofosbuvir
Achillion Pharmaceuticals announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Of the 12 patients treated, 100 percent remained HCV RNA undetectable four weeks after completing therapy. Based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir. "ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies. We believe these studies also confirm a differentiated efficacy profile for an NS5A inhibitor. Achieving 100% SVR4 with eight weeks of treatment with sofosbuvir serving as a nucleotide proxy indicate that dosing 50 mg once daily of ACH-3102 plus a nucleotide inhibitor has the potential to achieve commercially competitive results for curing HCV in a short duration, ribavirin-free doublet," commented David Apelian, EVP and Chief Medical Officer at Achillion. Milind Deshpande, President and CEO of Achillion commented, "As we continue to achieve clinical milestones, we remain focused on execution of the broader clinical development strategy for our HCV portfolio. We expect that Phase 1 proof-of-concept results with ACH-3422 will be reported during the fall of this year, which we anticipate will lead to the start of a Phase 2 combination program to evaluate our proprietary doublet regimen for an eight week, or potentially shorter, treatment regimen for HCV that will begin before the end of 2014."
06:17 EDTACHNAchillion initiated with an Outperform at FBR Capital
Subscribe for More Information
05:54 EDTSIRIStocks with implied volatility movement; GPRO SIRI
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use